Navigation Links
GM-CSF required for the immune attack in multiple sclerosis
Date:4/24/2011

This release is available in German.

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model. Unlike other known cytokines, they write in the journal Nature Immunology, this messenger substance is essential for the development of the disease. By the end of this year, a clinical trial will be launched in which GM-CSF is to be neutralized in MS patients.

The immune systems main task is to protect us from pathogenic microorganisms. To do so, an armada of immune cells is diligently instructed to search for invading pathogens. The ability of immune cells to communicate with one another is vital to this protection. Mistakes in the communication can lead to 'misunderstandings' and an erroneous attack against ones own tissues. Such is the case in autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis and juvenile diabetes, where the immune system inadvertently attacks the body. So-called helper T cells are chiefly responsible for the fatal immune response.

There are various sub-classes of helper T cells with different tasks and responsibilities. Clinicians and researchers have long been trying to ascertain which sub-class the rogue T cells that attack the body's own organs in autoimmune diseases actually belong to. T cells release certain messenger substances, known as cytokines, which in turn coordinate the appropriate immune response. Until now, the type of T-cell and, above all, the relevant cytokine that causes the inflammation in the brain and spinal cord were not known.

The research team of Professor Burkhard Becher has spent six years testing the relevant cytokines by a process of elimination in transgenic mouse models of multiple sclerosis. Over the years, they were able to cross many factors off the list before eventually hitting the jackpot with GM-CSF (granulocyte macrophage colony-stimulating factor). GM-CSF is produced by a newly discovered subclass of helper T cells. "The MS-like disease could not be induced in mice without GM-CSF," says Becher. "What's more, the disease could even be cured in MS mice if the cytokine was neutralized."

GM-CSF is not a new cytokine; we already knew that it can cause or aggravate inflammation. Apart from GM-CSF, however, all the other cytokines studied thus far only played a minor role. "GM-CSF is therefore the first T-cell cytokine that's essential for the initiation of an inflammatory reaction," says Becher. Furthermore, the researchers were able to demonstrate that the GM-CSF delivered to the brain by T cells activates the recruitment of tissue-damaging scavenger cells. "Without scavenger cells like these, the inflammation can't really get going in the first place and the neutralization of GM-CSF can even reverse the inflammatory process," says the immunologist.

Patients suffering from rheumatoid arthritis are currently being treated with neutralizing antibodies against GM-CSF in a clinical trial. A trial with MS patients is due to begin at the end of 2011. "We're extremely hopeful," says Becher enthusiastically. "But whether this form of therapy will actually help MS patients remains to be seen. Quiet optimism is the way to go," he explains.

Irrespective of the clinical trial, the team expects the study to have a significant impact on basic and clinical research. "We're really making headway; we now understand much better how an inflammatory lesion can develop in the brain."


'/>"/>

Contact: Burkhard Becher
becher@immunology.uzh.ch
41-446-353-701
University of Zurich
Source:Eurekalert

Related medicine news :

1. Study finds more Americans bypassing their personal physician when immediate treatment required
2. De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V
3. Hopkins doctor/disaster expert says resource problems in Haiti required ethical decision-making
4. Signaling pathway reveals mechanism for B cell differentiation in immune response
5. Do Immune System Ills Help Drive Type 2 Diabetes?
6. New evidence that chronic ulcerative stomatitis is an autoimmune disease
7. A Pacman strategy to boost the immune system to fight cancer
8. Immune-Boost Treatment Might Help Some With Advanced Colon Cancer
9. Immune system may guide chemotherapy for breast cancer
10. NIH investigators find link between DNA damage and immune response
11. Case Western Reserve receives $1.6M to study tumor cells and immune cell detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... , ... September 26, 2017 , ... Data Integrity: , ... LLC **, Dec. 5-6, 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity ... findings indicate the firm’s electronic records may not be trustworthy and reliable … a ...
(Date:9/26/2017)... Colorado (PRWEB) , ... September 26, 2017 , ... ... Autism, LLC and expands services in Northern Colorado. Aspire Autism, A Division of ... based Applied Behavior Analysis (ABA) services. Aspire provides center based Autism services in ...
(Date:9/26/2017)... Pittsburgh, PA (PRWEB) , ... September 26, 2017 ... ... new chairmen who are collaborating on strategic and tactical plans for Pittcon 2018. ... Chemistry), took office as president along with his named vice president, Charles Gardner, ...
(Date:9/26/2017)... ... September 26, 2017 , ... “The Ballad of Cowboy Justin”: ... way. “The Ballad of Cowboy Justin” is the creation of published author, Leah Westbrook, ... Christian Faith Publishing, Leah Westbrook’s new book is a delightful tale about a young ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sonflower Submission”: a ... nature to the inevitable destinations of negativity, complaining and the need to always be ... take effect in order for a lesson in stress-less living to be learned. ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Morgan Stanley ... Grand Hyatt hotel in New York.  Zimmer Biomet will ... Eastern Time. A live webcast of the ... website at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... Sept. 5, 2017  Just 18 months after its ... pleased to announce the appointment of three new senior ... , Dominic Jones-Phillips and James Wright ... Tammy Wynne ... market access writers. She has over ten years, experience ...
Breaking Medicine Technology: